&nbsp;

FrequentlyAskedQuestions-OCRSEERStat12a.pdf

Jun 2021

Document

FullDocumentClinicianResource.pdf

Oct 2021

Document

FullDocumentClinicianResource-FR.pdf

Oct 2021

Regimen

XELOX+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Document

FormulaSedentaryTime-EN.JPG

Feb 2022

Document

FormulaSedentaryTime-FR.JPG

Feb 2022

Document

FITLabReportsPrimary.pdf

Mar 2022

Regimen

XELOX+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

XELOX

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet (XELOX)

Jan 2024

Document

food-literacy-en.png

Jan 2023

Document

food-literacy-fr.png

Jan 2023

Regimen

FEC+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used: